Project Grant R21CA288898
Award Date
12/13/24
Completion Date
11/30/26
Dollars Obligated
$226K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $644,190 to the Mayo Clinic to conduct research on "Metabolic Strategies to Eradicate Premalignant Clonal Plasma Cells and Prevent the Development of Multiple Myeloma." The award period runs from September 1, 2024 to August 31, 2026. The grant supports the Mayo Clinic's expertise in cancer research, clinical trials, and translational medicine to...
This $124,230 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research led by Dr. Parikh at the Mayo Clinic in Rochester, Minnesota. The key objectives are to: 1) Complete two ongoing clinical trials evaluating novel combination treatments for untreated chronic lymphocytic leukemia (CLL) patients, including data analysis and manuscript preparation; and 2) Develop the protocol and serve as the national principal investigator for...
The Defense Health Agency awarded a $597,543.00 Project Grant to Mayo Clinic Arizona, doing business as Mayo Clinic Hospital, a nonprofit academic medical center. The grant, which runs from October 1, 2023 to September 14, 2026, is funded under the Military Medical Research and Development program (CFDA 12.420) to support research aimed at "elucidating mechanisms of CAR-T cell immunotherapy resistance and sensitivity to improve treatment of myeloma." As a nonprofit organization with...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $564,900.00 to Mayo Clinic to support research aimed at "EXPLOITING VIRAL TROPISM TO TARGET CANCER-ASSOCIATED FIBROBLASTS IN INTRAHEPATIC CHOLANGIOCARCINOMA". The award period runs from September 1, 2024 to August 31, 2026. Mayo Clinic, a renowned non-profit academic medical center, will leverage its expertise in cancer biology, drug development,...
This Project Grant award, valued at $674,440 and provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research at the University of Miami aimed at comprehensively defining the clinical impact of myeloma-defining genomic and immune events among myeloma precursor conditions. The goal is to differentiate benign from malignant entities, enabling strategies for early prevention of multiple myeloma, a critical unmet clinical need. The research leverages novel...
This Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) provides $2,455,718.00 to Mayo Clinic in Rochester, Minnesota to conduct NKG7-armed tumor-infiltrating lymphocyte therapy research for metastatic uveal melanoma. The award period runs from September 1, 2025 through August 31, 2029. This research project aims to advance medical solutions for the battlefield and transform healthcare for military service members...
The federal Project Grant award of $161,400.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support Mayo Clinic's research project titled "AN ATLAS OF THE TUMOR IMMUNE CIRCULOME." This award, with a performance period from June 1, 2024 to May 31, 2025, aims to advance medical knowledge and improve patient care through innovative biomedical research. The Military Medical Research and Development program funds a wide range of...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the CFDA program "Discovery and Applied Research for Technological Innovations to Improve Human Health" (93.286), will support the development of AI-assisted photon-counting-detector CT imaging to improve cytogenetic risk prediction and treatment response assessment for multiple myeloma patients. The total award amount is $546,874, with a performance period from April 1, 2025 to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $691,118 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to establish a prospective cohort study of real-world multiple myeloma patients treated with chimeric antigen receptor (CAR) T-cell therapy. The study aims to evaluate the relationships between psychosocial factors (e.g., depression, anxiety, social support) and...
This federal Project Grant award of $1,782,155.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the Mayo Clinic in Rochester, Minnesota. The award, effective April 1, 2025 through March 31, 2028, supports research to identify novel drug targets for lethal prostate cancer using liquid biopsy techniques. As a leading academic medical center, Mayo Clinic will leverage its expertise in oncology research and clinical trials to...